In particular, genetic variants belonging to angiogenic mediators (CXCR4, CCL2, CXCL8, TBK1, IRF3) and tumor immune escape molecules (CD24, CTLA-4, CD274, IDO1) are mainly investigated in anti-VEGF and anti-EGFR therapies, respectively, generating promising, although preliminary data, suggesting a potential translation, after validation, into clinical practice. This evidence concerns the gene IDO1 and neoplasm.